HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

RDNT

RadNet, Inc. (NASDAQ)

Healthcare — Diagnostics & Research

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Strong Buy 1.3 / 5 8 analysts
$65.62
+$3.95 (+6.41%)
Target: $89.75 (36.8%)
Sign in to add RDNT to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$5.16B
P/E Ratio (TTM)-
Forward P/E69.56
EPS (TTM)$-0.17
Dividend Yield-
Profit Margin-0.66%
Revenue Growth22.10%
ROE1.77%
Debt/Equity143.00
Recommendation Strong Buy 1.3
Analyst Target$89.75
Analysts8
Indexes NASDAQ

Technical Indicators

RSI (14)67.1
Beta1.39
SMA 20-
SMA 40-
52-Week High$85.84
52-Week Low$50.76
50-Day Avg$56.26
200-Day Avg$67.83
Avg Volume877.7K
Volume$1.01M

Performance Analysis

BULLISH

RDNT shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 42% of its 52-week range.
+ RSI at 67.1 shows positive momentum.
+ Strong revenue growth of 22.1% year-over-year.
- Operating at a loss with -0.7% margin.
+ Wall Street consensus is "Strong Buy" from 8 analysts.
+ Average analyst target of $89.75 implies 36.8% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:28 UTC

Back to Screener Export Report